Loading stock…

Veracyte, Inc. (VCYT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Veracyte, Inc.

VCYTMarket cap $3.59BPrice $44.6

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops genomic tests that help doctors avoid unnecessary surgeries, especially for thyroid and lung conditions. Its Afirma test alone has spared over 50,000 patients from invasive biopsies by decoding cancer risk straight from a patient's own genes.

In Bastion Portfolios?

52W Return+25%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+20%9

Revenue Forecast

Rev CAGR (1y)+15%7

Rev CAGR (3y)+12%8

Rev CAGR (5y)+13%8

Earnings Forecast

EPS Growth Y+1+134%10

EPS Growth Y+2+4%5

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin16%6

Net Income Margin20%8

Free Cash Flow Margin30%9

Debt

Net Debt/EBITDA-3.410

Efficiency

ROE9%4

ROA8%8

Earnings Stability66

GEAR+STRONG71

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)253

P/E Ratio (Forward 3y)203

P/BV2.66

EV Multiples

EV/EBITDA Fwd212

EV/EBIT Fwd421

Yield

Free Cash Flow Yield4.6%6

Dividend Yieldna–

Momentum

Short term

1 month return+5%9

3 month return-20%2

YTD return+6%6

Mid term

Price vs 52wHigh73%4

1 year return+29%8

Long term

3 year return+107%8

5 year return+2%4

Risk Shield

Price Risk

Beta1.04

Volatility64%2

Free Cash Flow

Free Cash Flow Margin30%9

Free Cash Flow Yield4.6%6

Quality

ROCE7%4

Earnings Stability66

Net Debt/EBITDA-3.410

02Growth

Is it actually growing, and how fast?

VCYTVeracyte

Revenue FY25$517M

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+12%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+134%10

EPS growth, FY27E+4%5

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 12%/yr).

WATCH

Revenue grew 20%/yr over the last 3 years; forecasts see it cooling to 12%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return-20%2

YTD return+6%6

MID & LONG-TERM▾SCORE

% of 52-week high73%4

1-year return+29%8

3-year return+107%8

5-year return+2%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+5%).

WATCH

Average long-term results. Multi-year returns are middling (+107% over three years and +1.7% over five), roughly average for the market.

It's up 29% over the past year, but 27% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (+6%).

WEAKNESSES

The stock is underperforming over three months (-20%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Veracyte, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

VCYTVeracyte

Revenue FY25$517M

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+12%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+134%10

EPS growth, FY27E+4%5

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 12%/yr).

WATCH

Revenue grew 20%/yr over the last 3 years; forecasts see it cooling to 12%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return-20%2

YTD return+6%6

MID & LONG-TERM▾SCORE

% of 52-week high73%4

1-year return+29%8

3-year return+107%8

5-year return+2%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+5%).

WATCH

Average long-term results. Multi-year returns are middling (+107% over three years and +1.7% over five), roughly average for the market.

It's up 29% over the past year, but 27% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (+6%).

WEAKNESSES

The stock is underperforming over three months (-20%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Veracyte, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community